Lupin Limited has informed the Exchange regarding a press release dated January 21, 2026, titled Lupin and Galenicum Sign License and Supply Agreement for Semaglutide in 23 Countries.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has entered into a license and supply agreement with Galenicum to commercialize Semaglutide across 23 countries. Semaglutide is a GLP-1 receptor agonist widely used for diabetes and weight management, and this deal gives Lupin access to a high-demand therapeutic segment. The agreement allows Lupin to manufacture and supply the product, while leveraging Galenicum's regional distribution network. This expands Lupin's footprint in international markets and strengthens its portfolio in the chronic and lifestyle disease space. The move comes amid rising global demand for affordable Semaglutide alternatives as patents begin expiring in various regions.
Positive for shareholders — the deal opens a new, high-growth revenue stream across 23 countries and positions Lupin as a key player in the global Semaglutide market. Could support medium-term earnings growth and stock sentiment, though execution and regulatory approvals in each country will be key watchpoints.